Faron Pharmaceuticals Oy is a Finnish drug research and discovery company. The company is focused on developing novel therapeutics for medical conditions with unmet needs such as acute organ traumas, cancer immunotherapy, and vascular damage. Its pipeline of drugs is comprised of its lead product Traumakine (FP-1201-lyo) and Clevagen (FP-1304). Traumakine addresses Acute Respiratory Distress Syndrome and is currently in its phase-3 of development. Clevagen is an immunotherapy tumor targeting candidate that is in pre-clinical stage development. The Company's main sources of revenue have been upfront payments (one-off license payments), revenues from product sales and milestone payments in accordance with the license agreements.